Percutaneous transcatheter aortic valve implantation: Present and future perspective

Expert Review of Medical Devices

Volumn 10, Issue 2, 2013, Pages 185-199

  Fernández, Diego ^a   Cevallos, Joaquim ^a   Brugaletta, Salvatore ^a   Martín Yuste, Victoria ^a   Freixa, Xavier ^b   Andrea, Ruth ^a   Falces, Carlos ^a   Regueiro Cueva, Ander ^a   Masotti, Mónica ^a   Sabaté, Manel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

aortic stenosis; CoreValve ; Edwards SAPIEN XT ; PARTNER trial; transcatheter aortic valve implantation

Indexed keywords

AORTIC STENOSIS; BALLOON DILATATION; FUTURE PERSPECTIVES; PARTNER TRIAL; SHAPE-MEMORY MATERIALS; STANDARD OF CARES; THIRD GENERATION; TRANSCATHETER AORTIC VALVES;

BLOOD VESSELS; DISEASES; PATIENT TREATMENT;

PROSTHETICS;

NITINOL;

ANTICOAGULANT THERAPY; AORTA STENOSIS; AORTOGRAPHY; ATRIOVENTRICULAR BLOCK; BALLOON DILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DISEASE SEVERITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PROSTHETIC VALVE DYSFUNCTION; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL RISK; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; ANIMALS; AORTIC VALVE STENOSIS; BIOPROSTHESIS; CARDIAC CATHETERIZATION; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; PATIENT SELECTION; PROSTHESIS DESIGN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84874874083     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.12.78     Document Type: Review

References (101)

1. Holmes DR Jr, Mack MJ, Kaul S et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J. Am. Coll. Cardiol. 59(13), 1200-1254 (2012).
2. Bonow RO, Carabello BA, Kanu C et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114(5), e84-231 (2006).
3. Iung B, Baron G, Butchart EG et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur. Heart J. 24(13), 1231-1243 (2003).
4. Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106(24), 3006-3008 (2002).
5. Kim W-J. Learning from the cases of TAVI. Presented at: IPS Congress, London, UK, 20-22 September 2010.
6. Rodés-Cabau J. Transcatheter aortic valve implantation: current and future approaches. Nat. Rev. Cardiol. 9(1), 15-29 (2012).
7. Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. Circulation 108(8), 983-988 (2003).
8. Giannini C, Petronio AS, Talini E et al. Early and late improvement of global and regional left ventricular function after transcatheter aortic valve implantation in patients with severe aortic stenosis: an echocardiographic study. Am. J. Cardiovasc. Dis. 1(3), 264-273 (2011).
9. Rodés-Cabau J, DeLarochellière R, Dumont E. First-in-man transcatheter aortic valve implantation of a 20-mm Edwards SAPIEN XT valve: one step forward for the treatment of patients with severe aortic stenosis and small aortic annulus. Catheter. Cardiovasc. Interv. 79(5), 789-793 (2012).
10. Pasic M, Dreysse S, Drews T et al. Improved technique of transapical aortic valve implantation: 'the Berlin addition'. Ann. Thorac. Surg. 89(6), 2058-2060 (2010).
11. Mok M, Dumont E, Doyle D, Rodés- Cabau J. Transcatheter aortic valve implantation using the slow balloon inflation technique: making balloonexpandable valves partially repositionable. J. Card. Surg. 27(5), 546-548 (2012).
12. Chorianopoulos E, Krumsdorf U, Pleger ST, Katus HA, Bekeredjian R. Improved procedural results after CoreValve implantation with the new AccuTrak delivery system. J. Interv. Cardiol. 25(2), 174-179 (2012).
13. Tchetche D, Modine T, Farah B et al. Update on the need for a permanent pacemaker after transcatheter aortic valve implantation using the CoreValve® Accutrak™ system. EuroIntervention 8(5), 556-562 (2012).
14. Wood DA, Tops LF, Mayo JR et al. Role of multislice computed tomography in transcatheter aortic valve replacement. Am. J. Cardiol. 103(9), 1295-1301 (2009).
15. Tzikas A, Schultz C, Van Mieghem NM, de Jaegere PP, Serruys PW. Optimal projection estimation for transcatheter aortic valve implantation based on contrastaortography: validation of a Prototype Software. Catheter. Cardiovasc. Interv. 76(4), 602-607 (2010).
16. Dvir D, Kornowski R. Percutaneous aortic valve implantation using novel imaging guidance. Catheter. Cardiovasc. Interv. 76(3), 450-454 (2010).
17. Moat NE, Ludman P, de Belder MA et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the UK TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J. Am. Coll. Cardiol. 58(20), 2130-2138 (2011).
18. Gilard M, Eltchaninoff H, Iung B et al. FRANCE 2 Investigators. Registry of transcatheter aortic-valve implantation in high-risk patients. N. Engl. J. Med. 366(18), 1705-1715 (2012).
19. Ussia GP, Barbanti M, Petronio AS et al. CoreValve Italian Registry Investigators. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. Eur. Heart J. 33(8), 969-976 (2012).
20. Bosmans JM, Kefer J, De Bruyne B et al. Belgian TAVI Registry Participants. Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry. Interact. Cardiovasc. Thorac. Surg. 12(5), 762-767 (2011).
21. Buellesfeld L, Gerckens U, Grube E. Percutaneous implantation of the first repositionable aortic valve prosthesis in a patient with severe aortic stenosis. Catheter. Cardiovasc. Interv. 71(5), 579-584 (2008).
22. Falk V, Walther T, Schwammenthal E et al. Transapical aortic valve implantation with a self-expanding anatomically oriented valve. Eur. Heart J. 32(7), 878-887 (2011).
23. Kempfert J, Rastan AJ, Beyersdorf F et al. Trans-apical aortic valve implantation using a new self-expandable bioprosthesis: initial outcomes. Eur. J. Cardiothorac. Surg. 40(5), 1114-1119 (2011).
24. Kempfert J, Rastan AJ, Mohr FW, Walther T. A new self-expanding transcatheter aortic valve for transapical implantation - first in man implantation of the JenaValve ™. Eur. J. Cardiothorac. Surg. 40(3), 761-763 (2011).
25. Treede H, Mohr FW, Baldus S et al. Transapical transcatheter aortic valve implantation using the JenaValve™ system: acute and 30-day results of the multicentre CE-mark study. Eur. J. Cardiothorac. Surg. 41(6), e131-e138 (2012).
26. Willson AB, Rodès-Cabau J, Wood DA et al. Transcatheter aortic valve replacement with the St. Jude Medical Portico valve: first-in-human experience. J. Am. Coll. Cardiol. 60(7), 581-586 (2012).
27. Schofer J, Schlüter M, Treede H et al. Retrograde transarterial implantation of a nonmetallic aortic valve prosthesis in high-surgical-risk patients with severe aortic stenosis: a first-in-man feasibility and safety study. Circ. Cardiovasc. Interv. 1(2), 126-133 (2008).
28. Treede H, Tübler T, Reichenspurner H et al. Six-month results of a repositionable and retrievable pericardial valve for transcatheter aortic valve replacement: the direct flow medical aortic valve. J. Thorac. Cardiovasc. Surg. 140(4), 897-903 (2010).
29. Gaia DF, Palma JH, Ferreira CB et al. Transapical aortic valve implantation: results of a Brazilian prosthesis. Rev. Bras. Cir. Cardiovasc. 25(3), 293-302 (2010).
30. Gaia DF, Palma JH, Ferreira CB et al. Transcatheter aortic valve implantation: results of the current development and implantation of a new Brazilian prosthesis. Rev. Bras. Cir. Cardiovasc. 26(3), 338-347 (2011).
31. Levi DS, Kusnezov N, Carman GP. Smart materials applications for pediatric cardiovascular devices. Pediatr. Res. 63(5), 552-558 (2008).
32. Leon MB, Smith CR, Mack M et al. PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 363(17), 1597-1607 (2010).
33. Makkar RR, Fontana GP, Jilaihawi H et al. PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N. Engl. J. Med. 366(18), 1696-1704 (2012).
34. Smith CR, Leon MB, Mack MJ et al. PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N. Engl. J. Med. 364(23), 2187-2198 (2011).
35. Kodali SK, Williams MR, Smith CR et al. PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N. Engl. J. Med. 366(18), 1686-1695 (2012).
36. Hlatky MA, Simons CT. Cost-effectiveness of transcatheter aortic valve replacement. Circulation 125(9), 1076-1077 (2012).
37. Gurvitch R, Tay EL, Wijesinghe N et al. Transcatheter aortic valve implantation: lessons from the learning curve of the first high-risk patients. Catheter. Cardiovasc. Interv. 78(7), 977-984 (2011)
38. Leon MB, Piazza N, Nikolsky E et al. Standardized end point definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur. Heart J. 32(2), 205-217 (2011).
39. Wendler O. 30 Day outcome from the SOURCE XT TAVI post-approval Study. Presented at: EuroPCR. Paris, France, 15-18 May (2012).
40. Zahn R, Gerckens U, Grube E et al. German Transcatheter Aortic Valve Interventions-Registry Investigators. Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. Eur. Heart J. 32(2), 198-204 (2011).
41. Lefèvre T, Kappetein AP, Wolner E et al. PARTNER EU Investigator Group. One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. Eur. Heart J. 32(2), 148-157 (2011).
42. Eltchaninoff H, Prat A, Gilard M et al. FRANCE Registry Investigators. Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur. Heart J. 32(2), 191-197 (2011).
43. Thomas M, Schymik G, Walther T et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 124(4), 425-433 (2011).
44. Kahlert P, Knipp SC, Schlamann M et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 121(7), 870-878 (2010).
45. Ghanem A, Müller A, Nähle CP et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusionweighted magnetic resonance imaging. J. Am. Coll. Cardiol. 55(14), 1427-1432 (2010).
46. Rodés-Cabau J, Dumont E, Boone RH et al. Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. J. Am. Coll. Cardiol. 57(1), 18-28 (2011).
47. Nietlispach F, Wijesinghe N, Gurvitch R et al. An embolic deflection device for aortic valve interventions. JACC Cardiovasc. Interv. 3(11), 1133-1138 (2010).
48. Naber CK, Ghanem A, Abizaid AA et al. First-in-man use of a novel embolic protection device for patients undergoing transcatheter aortic valve implantation. EuroIntervention 8(1), 43-50 (2012).
49. Onsea K, Agostoni P, Samim M et al. First-in-man experience with a new embolic deflection device in transcatheter aortic valve interventions. EuroIntervention 8(1), 51-56 (2012).
50. Nuis RJ, Van Mieghem NM, Tzikas A et al. Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter. Cardiovasc. Interv. 77(6), 881-889 (2011).
51. Sinning JM, Ghanem A, Steinhäuser H et al. Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. JACC. Cardiovasc. Interv. 3(11), 1141-1149 (2010).
52. Elhmidi Y, Bleiziffer S, Piazza N et al. Incidence and predictors of acute kidney injury in patients undergoing transcatheter aortic valve implantation. Am. Heart J. 161(4), 735-739 (2011).
53. Houthuizen P, Van Garsse LA, Poels TT et al. Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation 126(6), 720-728 (2012).
54. Fraccaro C, Buja G, Tarantini G et al. Incidence, predictors, and outcome of conduction disorders after transcatheter self-expandable aortic valve implantation. Am. J. Cardiol. 107(5), 747-754 (2011).
55. Khawaja MZ, Rajani R, Cook A et al. Permanent pacemaker insertion after CoreValve transcatheter aortic valve implantation: incidence and contributing factors (the UK CoreValve Collaborative). Circulation 123(9), 951-960 (2011).
56. Fiorina C, Curello S, Maffeo D, Lorusso R, Chizzola G, Ettori F. Management of acute left main obstruction after transcatheter aortic valve replacement: the 'tunnel technique'. Cardiovasc. Revasc. Med. 13(2), 142.e5-142.e9 (2012).
57. Rodés-Cabau J, Dumont E, Doyle D. 'Valve-in-valve' for the treatment of paravalvular leaks following transcatheter aortic valve implantation. Catheter. Cardiovasc. Interv. 74(7), 1116-1119 (2009).
58. Zegdi R, Ciobotaru V, Noghin M et al. Is it reasonable to treat all calcified stenotic aortic valves with a valved stent? Results from a human anatomic study in adults. J. Am. Coll. Cardiol. 51(5), 579-584 (2008).
59. Schultz CJ, Weustink A, Piazza N et al. Geometry and degree of apposition of the CoreValve ReValving system with multislice computed tomography after implantation in patients with aortic stenosis. J. Am. Coll. Cardiol. 54(10), 911-918 (2009).
60. Hammerstingl C, Werner N, Nickenig G. Symptomatic paravalvular leakage after mechanical aortic valve replacement in a critically ill patient: why not just 'plug' the hole? Eur. J. Echocardiogr. 10(4), 576-578 (2009).
61. Shapira Y, Hirsch R, Kornowski R et al. Percutaneous closure of perivalvular leaks with Amplatzer occluders: feasibility, safety, and shortterm results. J. Heart Valve Dis. 16(3), 305-313 (2007).
62. Sarkar K, Sardella G, Romeo F et al. Transcatheter aortic valve implantation for severe regurgitation in native and degenerated bioprosthetic aortic valves. Catheter. Cardiovasc. Interv. doi:10.1002/ ccd.24479 (2012) (Epub ahead of print).
63. Greif M, Lange P, Mair H et al. Transcatheter Edwards Sapien XT valve in valve implantation in degenerated aortic bioprostheses via transfemoral access. Clin. Res. Cardiol. 101(12), 993-1001 (2012).
64. Pasic M, Unbehaun A, Dreysse S et al. Transapical aortic valve implantation after previous aortic valve replacement: clinical proof of the 'valve-in-valve' concept. J. Thorac. Cardiovasc. Surg. 142(2), 270-277 (2011).
65. Zahn R, Schiele R, Kilkowski C et al. Correction of aortic regurgitation after transcatheter aortic valve implantation of the Medtronic CoreValve™ prosthesis due to a too-low implantation, using transcatheter repositioning. J. Heart Valve Dis. 20(1), 64-69 (2011).
66. Dewey TM, Brown DL, Herbert MA et al. Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann. Thorac. Surg. 89(3), 758-767; discussion 767 (2010).
67. Abdel-Wahab M, Mostafa AE, Geist V et al. Comparison of outcomes in patients having isolated transcatheter aortic valve implantation versus combined with preprocedural percutaneous coronary intervention. Am. J. Cardiol. 109(4), 581-586 (2012).
68. Clavel MA, Webb JG, Rodés-Cabau J et al. Comparison between transcatheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction. Circulation 122(19), 1928-1936 (2010).
69. Muñoz-García AJ, Jiménez-Navarro MF, Rodríguez-Bailón I et al. Impact of transcatheter aortic valve implantation with the CoreValve prosthesis in patients with severe aortic stenosis and left ventricular dysfunction. Int. J. Cardiol. 157(1), 124-125 (2012).
70. D'Ancona G, Pasic M, Buz S et al. Transapical transcatheter aortic valve replacement in patients with cardiogenic shock. Interact. Cardiovasc. Thorac. Surg. 14(4), 426-430 (2012).
71. Doebler K, Boukamp K, Mayer ED. Indication and structures and management of transcatheter aortic valve implantation: a review of the literature. Thorac. Cardiovasc. Surg. 60(5), 309-318 (2012).
72. Gurvitch R, Wood DA, Tay EL et al. Transcatheter aortic valve implantation: durability of clinical and hemodynamic outcomes beyond 3 years in a large patient cohort. Circulation 122(13), 1319-1327 (2010).
73. Ussia GP, Scarabelli M, Mulè M et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am. J. Cardiol. 108(12), 1772-1776 (2011).
74. Walther T, Simon P, Dewey T et al. Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation 116(11 Suppl.), I240-I245 (2007).
75. Wenaweser P, Pilgrim T, Roth N et al. Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. Am. Heart J. 161(6), 1114-1124 (2011).
76. Motloch LJ, Rottlaender D, Reda S et al. Local versus general anesthesia for transfemoral aortic valve implantation. Clin. Res. Cardiol. 101(1), 45-53 (2012).
77. Sharp AS, Michev I, Maisano F et al. A new technique for vascular access management in transcatheter aortic valve implantation. Catheter. Cardiovasc. Interv. 75(5), 784-793 (2010).
78. Vergnat M, Finet G, Rioufol G, Obadia JF. Percutaneous femoral artery access with Prostar device for innovative mitral and aortic interventions. Eur. J. Cardiothorac. Surg. 39(4), 600-602 (2011).
79. Hayashida K, Lefèvre T, Chevalier B et al. True percutaneous approach for transfemoral aortic valve implantation using the Prostar XL device: impact of learning curve on vascular complications. JACC Cardiovasc. Interv. 5(2), 207-214 (2012).
80. Walther T, Kempfert J, Mohr FW. Transcatheter aortic valve implantation: surgical perspectives. Arch. Cardiovasc. Dis. 105(3), 174-180 (2012).
81. Latsios G, Gerckens U, Grube E. Transaortic transcatheter aortic valve implantation: a novel approach for the truly 'no-access option' patients. Catheter. Cardiovasc. Interv. 75(7), 1129-1136 (2010).
82. Bapat V, Khawaja MZ, Attia R et al. Transaortic Transcatheter Aortic valve implantation using Edwards Sapien valve: a novel approach. Catheter. Cardiovasc. Interv. 79(5), 733-740 (2012).
83. Nombela-Franco L, Rodés-Cabau J, Doyle D et al. Transaortic transcatheter aortic valve implantation: potential issues associated with the use of the ASCENDRA transapical delivery system. J. Card. Surg. 27(4), 438-440 (2012).
84. Witkowski A, Dabrowski M, Chmielak Z et al. Transcatheter aortic valve implantation using transfemoral/ transsubclavian or transapical approach: 30-day follow-up of the initial 30 patients. Kardiol. Pol. 69(2), 105-114 (2011).
85. Cioni M, Taramasso M, Giacomini A et al. Transaxillary approach: short- and mid-term results in a single-center experience. Innovations (Phila.) 6(6), 361-365 (2011).
86. Schäfer U, Ho Y, Frerker C et al. Direct percutaneous access technique for transaxillary transcatheter aortic valve implantation: 'the Hamburg Sankt Georg approach'. JACC Cardiovasc. Interv. 5(5), 477-486 (2012).
87. Chu MW, Falk V, Mohr FW, Walther T. Percutaneous endoscopic transapical aortic valve implantation: three experimental transcatheter models. Interact. Cardiovasc. Thorac. Surg. 13(3), 251-256 (2011).
88. Routledge HC, Lefevre T, Morice MC, De Marco F, Salmi L, Cormier B. Percutaneous aortic valve replacement: new hope for inoperable and high-risk patients. J. Invasive Cardiol. 19(11), 478-483 (2007).
89. Thomas M, Schymik G, Walther T et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 122(1), 62-69 (2010).
90. Rodés-Cabau J, Webb JG, Cheung A et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J. Am. Coll. Cardiol. 55(11), 1080-1090 (2010).
91. Gurvitch R, Toggweiler S, Willson AB et al. Outcomes and complications of transcatheter aortic valve replacement using a balloon expandable valve according to the Valve Academic Research Consortium (VARC) guidelines. EuroIntervention 7(1), 41-48 (2011).
92. Buchanan GL, Chieffo A, Montorfano M et al. The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIEN ™ and Medtronic CoreValve ReValving System® devices: the Milan registry. EuroIntervention 7(5), 556-563 (2011).
93. ClinicalTrials.gov identifier: NCT01559298. Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial [online]. http://clinicaltrials.gov/ct2/show/NCT015 59298?term= nct01559298&rank=1
94. ClinicalTrials.gov. REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Evaluation of Safety and Performance [online]. http://clinicaltrials.gov/ct2/ show/NCT016 27691?term=reprise&rank=2
95. ClinicalTrials.gov. Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis. http://clinicaltrials.gov/ct2/show/NCT014 75799?term= direct+flow&rank=1
96. ClinicalTrials.gov. Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial. http://clinicaltrials.gov/ct2/show/ NCT01348438
97. ClinicalTrials.gov. Assessment Of The 23MM St. Jude Medical Portico™ Transcatheter Aortic Valve Portico 23-TF EU (Portico 23TFEU). http://clinicaltrials.gov/ct2/show/NCT014 97418?term=portico+trial&rank=1
98. ClinicalTrials.gov. Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). http://clinicaltrials.gov/ct2/show/NCT015 86910?term=surtavi&rank=1
99. ClinicalTrials.gov. Transcatheter Versus Surgical Valve Implantation in Patients With Severe Aortic Valve Stenosis (TAVIvsSAVR). http://clinicaltrials. gov/ct2/show/NCT010 57173?term=tavivssavr&rank=1
100. ClinicalTrials.gov. Transcatheter Aortic Valve Implantation Without Predilation (SIMPLIFy TAVI). http://clinicaltrials.gov/ct2/show/NCT015 39746?term=simplify+tavi&rank=1
101. ClinicalTrials.gov. The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves. http://clinicaltrials.gov/ct2/show/NCT013 14313?term=partner+II&rank=1